Earnings summaries and quarterly performance for Kezar Life Sciences.
Executive leadership at Kezar Life Sciences.
Board of directors at Kezar Life Sciences.
Research analysts who have asked questions during Kezar Life Sciences earnings calls.
Recent press releases and 8-K filings for KZR.
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program
KZR
New Projects/Investments
Layoffs
Regulatory Update
- Kezar Life Sciences (KZR) announced a Type C meeting with the FDA Division of Hepatology and Nutrition for the first quarter to discuss the development of zetomipzomib in autoimmune hepatitis (AIH).
- The meeting will review a potential global, randomized Phase 2b clinical study of zetomipzomib, and Kezar has submitted pharmacokinetic and hepatic safety data along with an updated risk-mitigation plan to address prior FDA requirements.
- Kezar's CEO, Chris Kirk, highlighted the opportunity to collaborate with the FDA on key clinical trial parameters and the potential for zetomipzomib to change the treatment landscape for AIH, a disease with significant unmet medical need.
- The company is also evaluating strategic alternatives to maximize shareholder value, which has included a significant workforce reduction and other cost-containment measures.
Jan 9, 2026, 11:01 AM
Kezar Life Sciences Reports Q3 2025 Financial Results and Announces Strategic Review
KZR
Earnings
Layoffs
- Kezar Life Sciences reported a net loss of $11.2 million, or $1.53 per basic and diluted common share, for the third quarter ended September 30, 2025, compared to a net loss of $20.3 million in the prior year period.
- As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $90.2 million, a decrease from $132.2 million at December 31, 2024.
- The company is exploring strategic alternatives after being unable to align with the FDA on a potential registrational clinical trial for zetomipzomib.
- In connection with cost-containment, Kezar repaid a $6.3 million loan on October 20, 2025, and implemented a 70% workforce reduction (approximately 31 employees) on November 6, 2025, expecting $6.0 million in related costs in the fourth quarter of 2025.
Nov 12, 2025, 9:07 PM
Kezar Life Sciences Reports Q3 2025 Results and Strategic Restructuring
KZR
Earnings
Layoffs
Guidance Update
- Kezar Life Sciences reported a net loss of $11.2 million, or $1.53 per basic and diluted common share, for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held $90.2 million in cash, cash equivalents, and marketable securities.
- Kezar announced it was unable to align with the FDA on a potential registrational clinical trial for zetomipzomib in autoimmune hepatitis, leading to the initiation of a process to explore strategic alternatives and implement cost-containment measures.
- In line with these measures, Kezar repaid a $6.3 million loan on October 20, 2025, and on November 6, 2025, implemented a restructuring plan to reduce its workforce by approximately 70%, or 31 employees.
Nov 12, 2025, 9:01 PM
DelveInsight Reports Explosive Growth in KRAS Inhibitors Market
KZR
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- The KRAS inhibitors market is projected for explosive growth with a CAGR of 35% during the forecast period of 2025–2034.
- The market size reached USD 475 million in 2024 in leading markets, with the United States accounting for approximately 70% of this total.
- AVMAPKI + FAKZYNJA is anticipated to capture a larger market share than KRAZATI and LUMAKRAS, while Onvansertib is expected to generate the highest revenue among emerging therapies by 2034.
- Recent developments include the FDA granting Breakthrough Therapy designation to Eli Lilly's olomorasib in September 2025 and the FDA approval of Verastem Oncology's AVMAPKI + FAKZYNJA Co-Pack in May 2025 for KRAS-mutated recurrent LGSOC.
Nov 12, 2025, 6:00 PM
Kezar Life Sciences Presents PORTOLA Phase 2a Clinical Trial Results
KZR
- Kezar Life Sciences announced the presentation of positive Phase 2a PORTOLA clinical trial data for zetomipzomib in patients with autoimmune hepatitis (AIH) at The Liver Meeting 2025.
- In steroid-dependent patients, 36% treated with zetomipzomib achieved biochemical remission and were able to taper their daily steroid dose to guideline levels, compared to 0% in the placebo group.
- Zetomipzomib was generally well-tolerated, with fewer infections reported in the treatment group relative to placebo.
- Analysis of circulating biomarkers showed meaningful changes across immune pathways, with shifts correlating with clinical responses.
Nov 7, 2025, 12:01 PM
Kezar Life Sciences Announces Regulatory Setback for Zetomipzomib and Explores Strategic Alternatives
KZR
M&A
Layoffs
- Kezar Life Sciences announced regulatory challenges with the FDA regarding its zetomipzomib program for autoimmune hepatitis, including a cancelled Type C meeting and requirements that will delay future trials by approximately 2 years.
- The company is initiating a process to explore a full range of strategic alternatives focused on maximizing shareholder value and has retained TD Cowen to support this review.
- As part of the strategic review, Kezar will implement a restructuring plan, including a workforce reduction and other cost-containment measures.
- Kezar reported preliminary cash, cash equivalents, and marketable securities of approximately $90.2 million as of September 30, 2025.
- The Board of Directors amended its limited duration stockholder rights plan, extending its expiration to the day following the certification of voting results of the 2026 annual meeting or, if approved by stockholders, the 2027 annual meeting.
Oct 16, 2025, 8:22 PM
Kezar Life Sciences Faces Regulatory Setback for Zetomipzomib and Explores Strategic Alternatives
KZR
Layoffs
M&A
- Kezar Life Sciences announced regulatory challenges for its zetomipzomib program in autoimmune hepatitis (AIH), including the FDA's cancellation of a Type C meeting and a requirement for a stand-alone pharmacokinetic study that would delay future trials by approximately 2 years.
- The company expressed disappointment with the FDA's decision, citing a lack of resources to extend the development timeline and questioning the feasibility of required 48-hour patient monitoring.
- In response, Kezar is exploring a full range of strategic alternatives to maximize shareholder value, has retained TD Cowen, and will implement a restructuring plan including a workforce reduction.
- As of September 30, 2025, Kezar reported approximately $90.2 million in cash, cash equivalents, and marketable securities.
- The company's Board of Directors has extended its limited duration shareholder rights plan to protect shareholder interests during the strategic review process.
Oct 16, 2025, 8:05 PM
Quarterly earnings call transcripts for Kezar Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more